Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Medivir.

    Client Virtual Booth

    MEDIVIR

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Medivir
    Sweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Box 1086 SE-141 22 Huddinge
    Telephone
    Telephone
    +46 (0)8 5468 31 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.medivir.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    FDA Grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the Treatment of Legg-Calvé-Perthes Disease

    Details:

    MIV-711 is a potent and selective inhibitor of cathepsin K, the principal protease involved in breaking down collagen in bone and cartilage. It is being evaluated for the treatment of Legg-Calvé-Perthes Disease.


    Lead Product(s): MIV-711

    Therapeutic Area: Rare Diseases and Disorders Product Name: MIV-711

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 25, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medivir Carries Out a Directed Share Issue of Approx. SEK 20 Million

    Details:

    Medivir is focusing on the development of MIV-818 (fostroxacitabine bralpamide), a pro-drug designed to selectively treat hepatocellular carcinoma (HCC).


    Lead Product(s): Fostroxacitabine Bralpamide,Pembrolizumab

    Therapeutic Area: Oncology Product Name: MIV-818

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Hallberg Management AB

    Deal Size: $12.3 million Upfront Cash: Undisclosed

    Deal Type: Private Placement January 22, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Quotient Sciences Supports Medivir with Updated Formulation of Fostrox

    Details:

    MIV-818 (fostroxacitabine bralpamide) is DNA inhibitor. It is being evaluated under phase 1/2 clinical development in combination with Lenvima (lenvatinib) for the treatment of hepatocellular carcinoma.


    Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib

    Therapeutic Area: Oncology Product Name: MIV-818

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Quotient Sciences

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medivir Announces Updated Formulation of Fostrox, Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

    Details:

    Fostrox (fostroxacitabine bralpamide) is an oral nucleotide DNA polymerase inhibitor. It is being developed for the treatment of patients with hepatocellular carcinoma (HCC).


    Lead Product(s): Fostroxacitabine Bralpamide

    Therapeutic Area: Oncology Product Name: Fostrox

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medivir to Report New and Updated Data from Ongoing Phase 2a HCC Study as Part of its Q3 Report on Friday

    Details:

    MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.


    Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib

    Therapeutic Area: Oncology Product Name: MIV-818

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 25, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Fostrox + Lenvima Continues to Show Promising Tumor Control in HCC, all Patients Have now Dosed at Least two Treatment Cycles

    Details:

    MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.


    Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib

    Therapeutic Area: Oncology Product Name: MIV-818

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medivir's Partner Tango Therapeutics Received FDA Clearance to Start the TNG348 Phase 1/2 Clinical Study

    Details:

    TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers.


    Lead Product(s): TNG348

    Therapeutic Area: Oncology Product Name: TNG348

    Highest Development Status: IND EnablingProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Tango Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 11, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medivir Reports Promising Interim Data, Including a First Complete Response in Phase 1B/2A HCC Study with Fostrox in Combination with Lenvima

    Details:

    MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated in with fostrox in combination with Lenvima for the treatment of primary liver cancer.


    Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib

    Therapeutic Area: Oncology Product Name: MIV-818

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 04, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Promising Tumor Control for Fostrox in Combination with Lenvima in Ongoing Phase 2a Study in HCC, 15th Patient Included

    Details:

    MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated for the treatment of primary liver cancer.


    Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib

    Therapeutic Area: Oncology Product Name: MIV-818

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 14, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medivir's Patent Application for Fostrox Approved in China

    Details:

    MIV-818 (fostroxacitabine bralpamide) is an orally active troxacitabine-based nucleotide prodrug, which is investigated for the treatment of primary liver cancer.


    Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib

    Therapeutic Area: Oncology Product Name: MIV-818

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 19, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search